BST2 and atherosclerosis: Importantly, the authors demonstrated that treatment with pDC-targeting Ab [plasmacytoid dendritic cell antigen-1 (BST2/PDCA-1/CD317)], previously used to investigate pDCs in experimental atherosclerosis, was not fully selective, leading to partial (albeit not significant) aortic macrophage depletion.